Table 3.
Multivariate analysis of survival according to pathological characteristics, TGF-β pathway, and TMB (cut-off 20%)
| DFSa |
OSa |
||||||
|---|---|---|---|---|---|---|---|
| Patients n (%) | HR | 95% CI (HR) | P value | HR | 95% CI (HR) | P value | |
| Total | 151 (100) | ||||||
| TMB (cut-off 20%) | 0.57 | 0.27-1.2 | 0.13 | 0.36 | 0.18-0.74 | 0.005 | |
| Low | 121 (80) | ||||||
| High | 30 (20) | ||||||
| AJCC stage | 1.91 | 1.34-2.7 | <0.001 | 1.40 | 1.09-1.80 | 0.008 | |
| Stage I | 20 (13) | ||||||
| Stage II | 36 (24) | ||||||
| Stage III | 30 (20) | ||||||
| Stage IV | 65 (43) | ||||||
| HPV | 0.40 | 0.06-2.9 | 0.37 | 0.52 | 0.13-2.14 | 0.37 | |
| Positive | 7 (5) | ||||||
| Negative | 144 (95) | ||||||
| Extranodal spreadb | 1.61 | 0.86-3.0 | 0.14 | 1.63 | 0.96-2.76 | 0.07 | |
| Negative | 111 (74) | ||||||
| Positive | 38 (26) | ||||||
| Invaded margins | 1.07 | 0.50-2.3 | 0.87 | 1.25 | 0.68-2.30 | 0.47 | |
| Negative | 127 (86) | ||||||
| Positive | 24 (16) | ||||||
| TGF-β pathway | 4.03 | 1.39-11.7 | 0.01 | 3.26 | 1.26-8.40 | 0.01 | |
| Unaltered | 6 (4) | ||||||
| Altered | 145 (96) | ||||||
95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; DFS, disease-free survival; HPV, human papillomavirus; HR, hazard ratio; OS, overall survival; TGF-β, transforming growth factor-β; TMB, tumor mutational burden.
Significant values are indicated in bold.
a
Cox model.
b
Information available for 149 patients.